News & Events

< Back to News Overview

Portland Orthopaedics' M-COR primary hip implants commence in US FDA approval in July and first three centres come on line in the USA

25 / 09 / 2006

Portland Orthopaedics Limited (ASX:PLD) first set of M-COR primary hip replacements have been implanted in three separate centres across the USA over the last week.

The first implants in 6 patients follow US FDA approval of Portland's M-COR primary hip series in July and the recent sales order announcements from US distributor Plus Orthopedics Inc. for more than $2.02 million of start up inventory. Implants are expected to ramp up over the coming weeks as Portland is able to deliver inventory currently in production.

The M-COR primary hip is Portland's second product now available for sale in the US and is used for primary (first time) hip replacement patients. The M-COR is modular with a distinct neck component designed for better fit and adjustability. It is fixed in the thigh bone (femur) by hammering and its uniqueness enables the surgeon to obtain an ideal fit for each person's anatomy.
Mr Craig Grabell, General Manager of Plus Orthopedics USA said, "Plus Orthopedics USA is very confident that we will have significant success in taking market share with the M-COR Stem. The M-COR stem is the next generation in total hip arthroplasty with novel innovation over the conventional stems in the US market. I am very enthusiastic that we will achieve our goals with Portland Orthopaedics."

Portland now has products for use in both Primary and Revision surgery available for sale through its exclusive distributor, Plus Orthopedics Inc in the USA. Portland's production capabilities are currently being expanded and more surgeons are expected to commence using the product as inventory is made available.